Table 2.
Immune related adverse events (irAEs) and rheumatoid arthritis (RA) flares among RA patients receiving Immune checkpoint inhibitor therapy (ICI)
| Characteristic | N=22 (%) |
|---|---|
| Developed irAEs | 7 (32) |
| Did not develop irAEs | 15 (68) |
| Types of irAE | |
| Dermatitis | 4 (18) |
| Colitis | 3 (14) |
| Hepatitis | 1 (5) |
| Median time to irAE, months (IQR) | |
| Colitis | 3 (3.5) |
| Dermatitis | 1 (8.5) |
| All irAEs | 1 (3.5) |
| Severity of irAEs | |
| Grade 1–2 irAEs | 5 (23) |
| Grade 3 irAEs* | 2 (9) |
| irAE management | N=7 |
| Systemic corticosteroids | 4 (57) |
| Topical steroids/Supportive Treatment | 4 (57) |
| ICI use at time of irAE | |
| Permanently discontinued | 1 (5) |
| Temporarily discontinued | 5 (23) |
| ICI continued after irAE | 1 (5) |
| RA Flares | |
| Developed a flare | 12 (55) |
| Did not develop a flare | 10 (45) |
| Median time to flare, months (IQR) | 1 (1.75) |
| Flare treatment | N=12 |
| Oral prednisone | 10 (83) |
| NSAIDs | 2 (17) |
| Methotrexate^ | 1 (8) |
| Sulfasalazine^ | 1 (8) |
| Prednisone equivalent dose for flare (mg/day) | |
| >40 mg | 4 (33) |
| <20 mg | 6 (50) |
| ICI use at time of flare | |
| Permanently discontinued | 2 (9) |
| Temporarily discontinued | 1 (5) |
| ICI continued | 9 (41) |
*
no grade 4 or 5 irAEs occurred
^
Used in combination with oral prednisone
Abbreviations: IQR-interquartile range